inthey clearly demonstrate that still areas both in relation to the actual toxicity the vacines and ajumants and to risks as unknown manufacturers themselves
In the first instance, they clearly demonstrate that there are still grey areas, both in relation to the actual toxicity of the vaccines and adjuvants and in relation to possible risks as yet unknown to the manufacturers themselves.
In they clearly demonstrate that still areas, both in relation to the actual toxicity the vaccines and adjuvants and to risks as unknown manufacturers themselves.